3results about How to "Protect kidney function" patented technology

This invention relates to a traditional Chinese medicine composition, specifically a traditional Chinese medicine composition for treating diabetic nephropathy, belonging to the fields of medicine and health products. The traditional Chinese medicine composition of this invention is made from components comprising the following raw materials: yam, salvia miltiorrhiza, rosehip, turtle shell, cornus officinalis, dioscorea hypoglauca, cuscuta chinensis, oyster shell, and American ginseng. Through rational formulation, this traditional Chinese medicine composition utilizes the principle of clearing heat and removing dampness, with the synergistic effect of multiple drugs, to significantly reduce fasting blood glucose, improve glucose metabolism, lower low-density lipoprotein cholesterol and triglycerides, and raise high-density lipoprotein cholesterol to regulate lipid metabolism, reduce weight, and has no significant damage to liver and kidney function, with minimal side effects.

The invention discloses application of serum alpha-non-red blood cell ghost protein 1 in preparation of drugs for diagnosing heart light chain amyloidosis diseases, and belongs to the technical field of biological medicines. The serum SPTAN1 protein is used for preparing the medicine for diagnosing the heart light-chain amyloidosis disease, the medicine is limited to be an enzyme linked immunosorbent assay kit, and the kit comprises an antibody of the SPTAN1 protein and further comprises a pre-coated plate, a standard substance, a coating buffer solution, a sample diluent, a confining liquid, horse radish peroxidase, an eluent and a color developing agent. The concentration of the SPTAN1 protein in the serum is measured through an enzyme linked immunosorbent assay kit, and early diagnosis of the heart AL amyloidosis disease is carried out. The invention provides a novel, efficient and sensitive biomarker, namely the serum SPTAN1 protein, early diagnosis of heart AL amyloidosis is realized by detecting the concentration of the SPTAN1 protein in serum, and the serum SPTAN1 protein has an important clinical application prospect.

The application belongs to the field of clinical drug toxic side effects, and particularly relates to the use of phenazine-1-carboxylic acid in treating cisplatin-mediated acute kidney injury. The application first discovers and proves that phenazine-1-carboxylic acid can effectively alleviate cisplatin-induced acute kidney injury. In a cisplatin-induced acute kidney injury model of mice, intraperitoneal injection of phenazine-1-carboxylic acid can effectively protect kidney function, which is specifically manifested as follows: significantly reducing urea nitrogen and creatinine levels in serum of model mice; reducing pathological injury of kidney tissue and reducing tubular injury score; and inhibiting expression of inflammatory factors and injury markers in kidney tissue. The treatment effect is equivalent to that of a classic ferroptosis inhibitor, Ferrostatin-1, and a new candidate drug for solving the dose-limiting toxicity of cisplatin in clinical application is provided.